This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (1)  • Contact me when this article is cited  Related Content  • Related article  • Similar articles in this journal  Topic Collections  • Neurology  • Multiple Sclerosis/ Demyelinating Disease  • Neuro-ophthalmology  • Diagnosis  • Immunologic Disorders  • Alert me on articles by topic  Social Bookmarking   What's this?

Setty M. Magaña, BS; Sean J. Pittock, MD; Vanda A. Lennon, MD, PhD; B. Mark Keegan, MD; Brian G. Weinshenker, MD; Claudia F. Lucchinetti, MD

Arch Neurol. 2009;66(8):964-966.

Background  The aquaporin-4–specific serum autoantibody neuromyelitis optica (NMO) IgG is a validated biomarker distinguishing NMO spectrum disorders from multiple sclerosis (MS). Because fulminant attacks are more common in NMO spectrum disorders than in MS, some investigators suggest that NMO IgG may be a marker of destructive demyelination rather than a disease-specific biomarker. To our knowledge, this study is the first to compare NMO IgG serostatus among patients with fulminant central nervous system inflammatory demyelinating disease (CNS IDD).

Objective  To determine whether NMO IgG distinguishes patients with NMO spectrum disorders from those with other fulminant corticosteroid-refractory CNS IDD.

Design  Descriptive historical cohort.

Setting  Neuroimmunology laboratory and neurology practice, Mayo Clinic College of Medicine, Rochester, Minnesota.

Patients  Serum samples from 74 patients who underwent plasmapheresis between February 24, 1993, and November 22, 2007, for a corticosteroid-refractory CNS IDD were tested for NMO IgG by indirect immunofluorescence assay.

Main Outcome Measures  Two blinded observers scored serum samples tested at 1:120 dilution. Clinical data were obtained by medical record review.

Results  Preplasmapheresis serum samples were available from 74 patients (ratio of women to men, 2:5); the mean interval between blood draw and plasmapheresis was 13 days. At the time of plasmapheresis, the mean age of patients was 46 years (age range, 7-80 years); the mean Expanded Disability Status Scale score was 7.0 (score range, 3.5-9.5 [10.0 is death]). Diagnoses included MS (18 patients with definite and 11 patients with probable), longitudinally extensive transverse myelitis involving at least 3 vertebral segments (20 patients), NMO (14 patients), transverse myelitis involving fewer than 3 vertebral segments (8 patients), optic neuritis (2 patients), and acute disseminated encephalomyelitis (1 patient). Neuromyelitis optica IgG was detected in 20 patients (27%) (10 with longitudinally extensive transverse myelitis, 9 with NMO, and 1 with recurrent optic neuritis) and was not detected in any patient with MS, short transverse myelitis, monophasic optic neuritis, or acute disseminated encephalomyelitis.

Conclusion  Neuromyelitis optica IgG is a specific biomarker for NMO spectrum disorders and is not simply a marker of destructive CNS IDD.

Author Affiliations: Departments of Neurology (Ms Magaña and Drs Pittock, Lennon, Keegan, Weinshenker, and Lucchinetti), Laboratory Medicine and Pathology (Drs Pittock and Lennon), and Immunology (Dr Lennon), Mayo Clinic College of Medicine, Rochester, Minnesota.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

RELATED ARTICLE

This Month in Archives of Neurology
Arch Neurol. 2009;66(8):929-930.
FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Neuromyelitis Serostatus in Fulminant CNS Demyelinating Disease
JWatch Neurology 2009;2009:2-2.
FULL TEXT